Les scientifiques viennent d'identifier une nouvelle cible pour le traitement de la leucémie myéloïde aiguë, soit la protéine Brd4. Déjà
la molécule JQ1 permet de supprimer la protéine Brd4 in vivo et in vitro .
"We found that suppressing Brd4 in turn depletes the level and activity of a protein called Myc, which is thought to maintain leukemic stem cells,"
Extrait de http://www.cshl.edu/Article-Vakoc/uncon ... r-leukemia
"Suppression of Brd4 using shRNAs or the small-molecule inhibitor JQ1 led to robust antileukaemic effects in vitro and in vivo, accompanied by terminal myeloid differentiation and elimination of leukaemia stem cells. Similar sensitivities were observed in a variety of human AML cell lines and primary patient samples, revealing that JQ1 has broad activity in diverse AML subtypes."
Extrait de http://www.nature.com/nature/journal/va ... 10334.html
Autres liens:
http://www.eurekalert.org/pub_releases/ ... 072911.php
http://www.sciencecodex.com/unconventio ... r_leukemia